Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Digital Stratification of BAP1-mutant Cancers (BAP-1)

Development of Digital Biomarkers for BAP1 Mutated Cancers (German Cancer Aid)

The project centers around BAP1, a tumor suppressor gene often mutated in aggressive cancers. Specifically, BAP1 mutations lead to increased tumor aggressiveness and metastasis. The goal of this project is to understand and target a vulnerability of BAP1 mutations for potential therapies in BAP1-mutant cancers. To achieve this, a collaborative consortium has been formed with subprojects focusing on providing necessary materials, testing specific drugs in vitro, in vivo and in patient-derived organoids, as well as conducting biomarker analyses on large human tissue cohorts. The overall aim is to validate the proposed mechanism and explore potential treatments, with an emphasis on initiating clinical trials based on the findings. The project integrates diverse approaches, including in vitro, in vivo, ex vivo, and clinical sample analyses, to comprehensively investigate BAP1-mutant cancers and develop personalized medicine strategies. Within this consortium, our group is responsible for digital biomarker development for improved patient stratification.

to top
powered by webEdition CMS